AstraZeneca Reportedly Cuts 600 U.S. Sales Positions While Redirecting Capital Toward Its Pipeline

Bloomberg News, as reported by Reuters, said AstraZeneca had cut approximately 600 positions in its U.S. respiratory and immunology commercial teams as part of a three-year cost-reduction initiative. The restructuring follows a previously announced plan targeting approximately $1.5 billion in annual savings, with funds intended for reinvestment in drug development. Some employees may be reassigned, and AstraZeneca declined to comment on the reported reductions. The company's respiratory and immunology portfolio generated approximately $2.5 billion in third-quarter revenue, representing 16% of total revenue.

Reuters

Reuters, citing Bloomberg · November 13, 2026

Why it matters strategically

Pharmaceutical companies increasingly face decisions about reallocating resources between mature commercial portfolios and development pipelines.

Reducing field-force expenditure can improve near-term margins, but may also affect physician engagement, product adoption, and revenue durability.

Previous
Previous

Eli Lilly Reports New Obesity Combination and Adolescent Phase III Results

Next
Next

Merck KGaA Raises Guidance Again as Life Science and Electronics Reshape Its Portfolio